MedNet Solutions and Alquest LLC, a CRO specializing in medical devices, in vitro diagnostics (IVDs), biologics, and combination products, are pleased to jointly announce that Alquest has become the first organization to join the iMedNet CRO Partner Program. Introduced last month by MedNet Solutions, the iMedNet CRO Partner Program aims to help Clinical Research Organizations (CROs) improve research efficiency, expand their service offerings, decrease internal costs, and win more business.
"We're delighted to be the first iMedNet CRO Partner with MedNet Solutions," stated Linda Alexander, Chief Executive Officer of Alquest. "Their new iMedNet EDC solution builds on the success of their proven ENLIGHTEN® software and brings eClinical capabilities to a whole new level. I'm excited to show this to our clients and provide them with this state-of-the-art solution."
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.